Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer
Cancer Letters · 2026-01 · 636 · 218006
DOI: 10.1016/j.canlet.2025.218006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Letters, 2026-01. Verfasst von Wentao Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Mi…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Jiangsu Hengrui Medicine.
Abstract (Originalsprache)
Locally advanced rectal cancer (LARC) remains challenging to treat due to high recurrence rates and limited therapeutic options, particularly for patients with high-risk features. This prospective, multicenter, single-arm, open-label phase 2 trial (ClinicalTrials.gov identifier: NCT05300269) evaluated the efficacy and safety of SHR-1701, a novel bifunctional fusion protein targeting both PD-L1 and TGF-β, in combination with neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) for high-risk LARC. Eligible patients had at least one high-risk factor, including cT3c-d or cT4 tumors, positive mesorectal fascia, extramural vascular invasion, or involvement of ≥4 lymph nodes. Patients received concurrent SHR-1701 and CRT, followed by two cycles of SHR-1701 plus XELOX and subsequent TME surgery. Postoperatively, patients underwent six additional cycles of SHR-1701 plus XELOX. The primary endpoints were pathological complete response (pCR) rate and safety. Among the 37 enrolled patients, 36 (97.3 %) completed the planned full-dose radiotherapy (50.4 Gy in 28 fractions) and subsequently underwent surgery. The pCR rate was 36.1 % (13/36). The median intervals from neoadjuvant therapy initiation to surgery and from surgery to adjuvant therapy were 112 days (range, 95-139) and 29 days (range, 22-59), respectively. The median follow-up was 9.9 months (range, 2-18) from the first dose of capecitabine. Grade ≥3 treatment-related adverse events during neoadjuvant therapy occurred in 40.5 % (15/37) of patients, most commonly lymphopenia (37.8 %, 14/37) and anemia (5.4 %, 2/37). One patient experienced fatal immune-mediated myocarditis prior to surgery. Overall, the addition of SHR-1701 to CRT demonstrated encouraging efficacy and manageable safety in high-risk LARC, supporting further investigation in larger randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China.
- Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zheji…
- Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
- Department of Radiology, Zhongshan Hospital, Fudan University, and Shanghai Institute of Medical Imaging, Shanghai, China.
- Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China. Electronic address: xujm…
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- Jiangsu Hengrui Medicine
- Science and Technology Commission of Shanghai Municipality
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Tang, W., Lv, Y., Xie, H., Wei, Y., Wang, J., Yu, M., Jiang, Y., Mao, R., Huang, C., Rao, S., Ding, K., Chang, W., He, G., & Xu, J. (2026). Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Cancer Letters, 636, 218006. https://doi.org/10.1016/j.canlet.2025.218006
Vancouver
Tang W, Lv Y, Xie H, Wei Y, Wang J, Yu M, et al. Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Cancer Letters. 2026;636:218006. doi:10.1016/j.canlet.2025.218006
BibTeX
@article{Tang2026,
author = {Tang, Wentao and Lv, Yang and Xie, Haiting and Wei, Ye and Wang, Jian and Yu, Mengzhu and Jiang, Yingyi and Mao, Rongfu and Huang, Chuanpei and Rao, Shengxiang and Ding, Kefeng and Chang, Wenju and He, Guodong and Xu, Jianmin},
title = {Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer},
journal = {Cancer Letters},
year = {2026},
volume = {636},
pages = {218006},
doi = {10.1016/j.canlet.2025.218006}
}
EUVIMED